Merck & Company, Inc. vs Natera, Inc. — Stock Comparison

MRK
Merck & Company, Inc.
$112.16
▲ 2.73%
vs
NTRA
Natera, Inc.
$207.28
▲ 0.54%
Q·Score Winner
Merck & Company, Inc.
MRK6.7/10vs 6/10

Q·Score Breakdown

6.7
Neutral
Overall
6
Neutral
6.2
Quality
2.5
7
Health
8.7
6.2
Growth
6.8
7.2
Valuation
5
7.1
Sentiment
8.2
MRK

Forward P/E of 11.5× is low relative to sector peers.

NTRA

Clean balance sheet with low leverage (0.1× debt-to-equity).

currently unprofitable (-9% margin).

Analyst Consensus

BUY
Target $129.74 (+15.7%)
27 analysts
BUY
Target $258.00 (+24.5%)
18 analysts

Fundamentals

MRK
NTRA
31.5×
Trailing P/E
11.5×
Forward P/E
-305.6×
13.6%
Profit Margin
-9.0%
76.6%
Gross Margin
64.7%
ROE
-14.3%
4.9%
Revenue Growth
39.8%
Earnings Growth
0.28
Beta
1.68
Price / Book
$277.0B
Market Cap
$29.6B
$73 – $125
52-Week Range
$132 – $256

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →